Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Dose-Escalation Study of PM14 in Advanced Solid Tumors
2024-511916-25-00Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ecubectedin in Nonhematologic neoplasms, sponsored by PharmaMar. Started Apr 2024; status: completed.
02
Drugs
ecubectedin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-511916-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511916-25-00.